Magpot MPS Oral Suspension is a combination antacid formulation containing Magaldrate 400 mg and Simethicone 20 mg per dose, designed for the symptomatic relief of gastrointestinal disturbances associated with hyperacidity and gas. Magaldrate, an aluminum and magnesium hydroxide complex, acts by neutralizing excess gastric acid, thereby increasing gastric pH and providing rapid relief from heartburn, acid indigestion, and dyspepsia. Simethicone, an anti-foaming agent, reduces bloating and discomfort caused by excessive gas accumulation by facilitating the coalescence and elimination of gas bubbles in the gastrointestinal tract. Magpot MPS is indicated for the management of conditions such as gastritis, peptic ulcer disease, gastroesophageal reflux, and flatulence. The oral suspension formulation allows for easy administration and rapid onset of action, making it suitable for both adults and pediatric patients requiring antacid therapy. It is generally well tolerated; however, prolonged use should be avoided without medical supervision to prevent potential alterations in electrolyte balance or masking of serious underlying conditions. Patients with renal impairment should use this medication cautiously. Magpot MPS Oral Suspension should be taken as directed by a healthcare professional, and consultation is advised if symptoms persist or worsen.